ClinicalTrials.gg
RecruitingNCT06932523Updated Jan 7, 2026

A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy Individuals

A Phase 1/2 interventional study of Recombinant herpes zoster vaccine with low-dose adjuvant and Recombinant herpes zoster vaccine with high-dose adjuvant in Herpes Zoster (HZ), sponsored by Shanghai Institute Of Biological Products. Recruiting at 1 site in China. Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-07.

Sponsored by Shanghai Institute Of Biological Products (part of Sinopharm) · Phase 1/2, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
645
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 51 studies in Herpes Zoster with a site in China — 26 open to participants now, 31 under way, 3 of them phase 3. Herpes Zoster · China.

Planned enrollment
20th of 45
645 · median 519
Started
2025
with 19 others
Phase 1/2
6 of 51
4 open now
Primary completion
2026-06
later than 12 of 30 live
Registered
31st of 51
by date
Lead sponsor
4 of 51
Shanghai Institute Of Biological Products

Among the 51 studies in Herpes Zoster with a site in China, this one is the 20th largest by planned enrollment of the 45 interventional ones that give a count, is one of 20 that started in 2025, is one of 6 in phase 1/2, reaches primary completion later than 12 of the 30 other live ones, and was the 31st registered.

Herpes Zoster

300 studies on the registry are indexed under Herpes Zoster; 56 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

26 of the 51 studies in Herpes Zoster with a site in China are open now. Recruiting first, the newest first:

20 more — sign in →

All 26 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 40 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Herpes Zoster with a site in China, or all of them as a file.
02

Study summary

The purpose of this clinical study is to evaluate the safety and immunogenicity of receiving two doses of recombinant herpes zoster vaccine (CHO cells) (RHZV) in healthy individuals aged 40 years and above. This study will be conducted in 2 substudies: Substudy A (Phase I) and Substudy B (Phase Ⅱ).

Read the detailed description

There are two parts of the study.

Substudy A:

This substudy is the Phase I portion of the study. In this substudy, participants will receive 1 of 2 RHZV candidates (different dose levels) or the approved shingles vaccine (positive control) or adjuvant controls or normal saline intramuscularly. Participants will be divided into 2 age groups: 40-49 years old and ≥ 50 years old. Participants will receive vaccinations on days 0 and 60. Participants will complete a 12-month safety follow-up after two doses of vaccination, and they will take part in this study for about 14 months.

Substudy B:

This substudy is the Phase Ⅱ portion of the study. In this part of the study, participants will also receive 1 of 2 RHZV candidates (different dose levels) or the approved shingles vaccine (positive control) or normal saline intramuscularly. Participants will be divided into 3 age groups: 40-49 years old, 50-69 years old and ≥ 70 years old. Participants will receive vaccinations on days 0 and 60. Some group(s) will continue into persistence-of-immunity (overtime assessment of effect of vaccine) portion of the study. Those participants will be involved in this study for up to 2 years.

03

Conditions studied

  • Herpes Zoster (HZ)

Browse trials for

Keywords

  • herpes zoster
  • recombinant herpes zoster vaccine
  • vaccine
  • safety
  • immunogenicity
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 40 years old on the day of enrollment, gender not limited.
  • Can provide legal proof of identity.
  • Be able to understand the experimental procedure and sign a written form, expressing agreement to participate in the experiment.
  • Be able to participate in all planned follow-up visits and comply with all trial procedures.
  • On the day of enrollment, the body temperature was less than 37.3 ℃ (axillary temperature).
  • Chronic disease patients need to be in a stable period of chronic disease.
  • Female and male participants of childbearing age agreed to adopt strict and effective measures from the start of the trial to 6 months after full exemption.

Exclusion criteria

Exclusion Criteria:

  • Individuals with a history of herpes zoster in the past.
  • Individuals with a history of vaccination against chickenpox or shingles.
  • Individuals who have had close contact with patients with chickenpox or shingles in the past 2 years.
  • Women of childbearing age who have a positive urine pregnancy test, are breastfeeding, pregnant, or plan to become pregnant within 6 months after the start of the test and the full exemption period.
  • Individuals who are allergic to any component of the vaccine or have a history of other severe allergies.
  • Use immunoglobulin and/or any blood products within 3 months prior to administering the trial vaccine, or plan to use them during the trial period.
  • Have taken antipyretic, analgesic, or anti allergic drugs within 72 hours prior to receiving the experimental vaccine.
  • Any experimental or unregistered product (drug, vaccine, biological product or device) other than the experimental vaccine has been used within one month prior to vaccination, or is planned to be used during the trial period.
  • Administer non within 7 days prior to administering the experimental vaccine or live vaccines within 14 days prior to administering the experimental vaccine.
  • Suffering from a serious illness that prevents the completion of the entire experiment.
  • Received therapy or other immunomodulatory drugs, monoclonal antibodies, thymosin, interferon, etc. within 6 months prior to vaccination with the experimental vaccine, or planned to receive such treatment within 1 month after the first dose to full immunization, but local medication is allowed.
  • Chemotherapy, radiotherapy, and organ and bone marrow transplantation related treatments for cancer or other diseases.
  • Diseases or medical measures that lead to immune dysfunction
  • Individuals currently suffering from serious infectious diseases such as active tuberculosis and active viral hepatitis.
  • Moderate or severe acute illness/infection, or febrile illness within 72 hours prior to vaccination.
  • Known to have a history of thrombocytopenia, any coagulation dysfunction, or being treated with anticoagulants.
  • Suffering from serious cardiovascular disease, pulmonary edema, serious liver and kidney disease, and diabetes that cannot be controlled by drugs.
  • Previous history of mental and neurological disorders or family history of mental illness.
  • Currently suffering from various severe infectious, suppurative, and allergic skin diseases.
  • Plan to move before the end of the trial or leave the local area for a long time during the scheduled trial visit.
  • (Phase I ) Abnormal blood routine, blood biochemistry, coagulation, and urine routine indicators before vaccination (excluding those judged by doctors to have no clinical significance).
  • Any situation that the researcher believes may affect the evaluation of the experiment.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
645 participants (estimated)

Study arms

  • Experimental
    SubStudy A (SSA): Group 1

    Recombinant herpes zoster vaccine with low-dose adjuvant

    Biological: Recombinant herpes zoster vaccine with low-dose adjuvant

  • Experimental
    SSA: Group 2

    Recombinant herpes zoster vaccine with high-dose adjuvant

    Biological: Recombinant herpes zoster vaccine with high-dose adjuvant

  • Placebo comparator
    SSA:Control group 1

    Low-dose adjuvant

    Biological: Low-dose adjuvant

  • Placebo comparator
    SSA:Control group 2

    High-dose adjuvant

    Biological: High-dose adjuvant

  • Active comparator
    SSA: Positive control

    Shingrix (GSK)

    Biological: Shingrix (GSK)

  • Placebo comparator
    SSA: Placebo group

    Normal saline

    Biological: Normal Saline

  • Experimental
    SubStudy B (SSB): Group 3

    Recombinant herpes zoster vaccine with low-dose adjuvant

    Biological: Recombinant herpes zoster vaccine with low-dose adjuvant

  • Experimental
    SSB: Group 4

    Recombinant herpes zoster vaccine with high-dose adjuvant

    Biological: Recombinant herpes zoster vaccine with high-dose adjuvant

  • Active comparator
    SSB: Positive control

    Shingrix (GSK)

    Biological: Shingrix (GSK)

  • Placebo comparator
    SSB: Placebo group

    Normal saline

    Biological: Normal Saline

Interventions

  • BiologicalRecombinant herpes zoster vaccine with low-dose adjuvant

    Candidate 1, Dose Level 1, Intramuscular injection, 0, 2 months schedule

  • BiologicalRecombinant herpes zoster vaccine with high-dose adjuvant

    Candidate 2, Dose Level 2, Intramuscular injection, 0, 2 months schedule

  • BiologicalLow-dose adjuvant

    Adjuvant control 1, Dose Level 1, Intramuscular injection, 0, 2 months schedule

  • BiologicalHigh-dose adjuvant

    Adjuvant control 2, Dose Level 2, Intramuscular injection, 0, 2 months schedule

  • BiologicalShingrix (GSK)

    Positive control, Intramuscular injection, 0, 2 months schedule

  • BiologicalNormal Saline

    Placebo control, Intramuscular injection, 0, 2 months schedule

06

What researchers measure

Primary outcomes

  1. Percentage of immediate Adverse Events (AEs)

    The occurrence of any adverse events within 30 minutes after each dose of vaccination.

    Time frame: 30min after each dose of vaccination

  2. Percentage of solicited Adverse Events

    Adverse events defined by the protocol that occurred to the participant during 0-14 days after each dose of vaccination.

    Time frame: 14 days after each dose of vaccination

  3. Serious Adverse Events (SAE)

    That is serious adverse events, any serious adverse events that occurred to the participant during the study period.

    Time frame: 12 months after the last dose

  4. Percentage of unsolicited Adverse Events

    Other adverse events that occurred among participants within 0-28/30 days after each vaccination, in addition to the solicited adverse events.

    Time frame: 28 or 30 days after each dose of vaccination

  5. Geometric Mean Concentration (GMC) of Anti-glycoprotein E (gE) Antibodies

    GMC levels o of Anti-gE Antibodies in participants after receiving 2 doses of vaccine.

    Time frame: 30 days after the last dose of vaccination

  6. Geometric Mean Titer (GMT) of Anti-VZV Antibodies

    GMT levels o of Anti-VZV Antibodies in participants after receiving 2 doses of vaccine.

    Time frame: 30 days after the last dose of vaccination

  7. Positive rate of Anti-gE Antibodies

    The proportion of individuals in the study population who have achieved Anti-gE antibody positive after immunization.

    Time frame: 30 days after the last dose of vaccination

  8. Positive rate of Anti-VZV Antibodies

    The proportion of individuals in the study population who have achieved Anti-VZV antibody positive after immunization.

    Time frame: 30 days after the last dose of vaccination

  9. Seroconversion rate of Anti-gE Antibodies

    The proportion of individuals in the study population who have achieved Anti-gE antibody seroconversion after immunization.

    Time frame: 30 days after the last dose of vaccination

  10. Seroconversion rate of Anti-VZV Antibodies

    The proportion of individuals in the study population who have achieved Anti-VZV antibody seroconversion after immunization.

    Time frame: 30 days after the last dose of vaccination

Secondary outcomes

  1. SSB: Cellular immune level

    Levels of glycoprotein E (gE)-specific CD4+/CD8+ T cells expressing 2 or more markers of activation.

    Time frame: 30 days, 6 months, 12months and 24 months after the last dose of vaccination

  2. SSB:Humoral immunogenicity level

    Levels of GMC (Anti-gE antibody), GMT (Anti-VZV antibody), positive rate and seroconversion rate after receiving 2 doses of vaccine.

    Time frame: 6 months, 12months and 24 months after the last dose of vaccination

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Jun 2026, 14 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2025
First posted
Apr 17, 2025
StartActual
Apr 4, 2025
Primary completionEst.
Jun 30, 2026
CompletionEst.
Dec 31, 2027
Last update
Jan 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06932523
Responsible party
Sponsor
First posted
Apr 17, 2025
Start date
Apr 4, 2025
Primary completion
Jun 30, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jan 7, 2026

Study contacts

Chaorong Xu
Contact
xuchaorong@sinopharm.com
02162800991
Yeqing Tong
principal investigator · Hubei Provincial Center for Disease Control and Prevention

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion